Key result
Mean platelet volume did not influence the risk of high on-treatment platelet reactivity for ADP-antagonists or aspirin.
Why the study?
Does mean platelet volume predict high on-treatment platelet reactivity in patients receiving dual antiplatelet therapy after acute coronary syndrome or PCI?
Observational (n=487)
Does mean platelet volume predict high on-treatment platelet reactivity in patients receiving dual antiplatelet therapy after acute coronary syndrome or PCI?
Mean platelet volume does not significantly affect the response to major antiplatelet therapies or the risk of high on-treatment platelet reactivity in patients on DAPT.
Answers are grounded in this paper and cite their sources.
Mean platelet volume should not guide DAPT selection or reactivity assessment; leaves open identification of reliable predictors after ACS or PCI.
OBJECTIVE: High on-treatment platelet reactivity (HRPR) is associated with a two- to ninefold increased risk of recurrent ischemic events among patients receiving dual antiplatelet therapy (DAPT) for coronary artery disease. However, its determinants are still poorly understood. The aim of the present study was to assess the impact of mean platelet volume (MPV) on platelet reactivity in patients receiving DAPT after an acute coronary syndrome or PCI. METHODS: Patients treated with DAPT (acetylsalicylic acid [ASA] and clopidogrel or ticagrelor) were scheduled for platelet function assessment at 30 - 90 days post-discharge. By whole blood impedance aggregometry, HRPR was considered for ASPI test > 862 aggregation units (AU)*min (for ASA) and ADP test values ≥ 417 AU*min (for ADP-antagonists). RESULTS: Our population is represented by a total of 487 patients on DAPT, divided according to MPV tertiles (< 10.4 fl; 10.4 - 11.29 fl; ≥ 11.3 fl). Larger-sized platelets were associated with use of statins (p < 0.001) and beta-blockers (p = 0.03), higher hemoglobin levels (p = 0.002) and lower platelets count (p < 0.001). Higher platelet reactivity was observed at ASPI test in patients with higher MPV (r = 0.12, p = 0.008), but not for ADP-mediated aggregation (r = -0.007, p = 0.88). However, a low prevalence of HRPR was observed with ASA, with no impact of MPV tertiles (1.2 vs 1.1 vs 1.6%, p = 0.70, adjusted OR [95% CI] = 1.05 [0.51 - 1.77], p = 0.87). MPV did not influence the prevalence of HRPR for ADP-antagonists (25.9 vs 1 vs 26.5%, p = 0.89; adjusted OR [95% CI] = 1.1 [0.84 - 1.45], p = 0.50) with similar results among the 259 patients receiving clopidogrel (adjusted OR [95% CI] = 1.15 [0.82 - 1.62], p = 0.43) and the 228 patients on ticagrelor (adjusted OR [95% CI] = 1.46 [0.84 - 2.55], p = 0.18). CONCLUSION: In patients receiving DAPT, MPV does not affect the response to major antiplatelet therapies. In fact, MPV elevation does not influence the risk of HRPR with clopidogrel, ticagrelor or ASA.
No takes yet. Share an insight, caveat, or question.
Verdoia et al. (2015) conducted an observational in Coronary artery disease receiving DAPT after ACS or PCI (n=487). Mean platelet volume (MPV) vs. Lower MPV tertiles was evaluated on High on-treatment platelet reactivity (HRPR) for ADP-antagonists (adjusted OR 1.1, 95% CI 0.84 - 1.45, p=0.50). Mean platelet volume did not influence the risk of high on-treatment platelet reactivity for ADP-antagonists or aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: